CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0001096: KeratoconjunctivitisHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug3499 topical steroids and cyclosporin-A Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007637 Keratoconjunctivitis NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

NCT04451239 Keratonjunctivitis Drug: topical steroids and cyclosporin-A
MeSH:Keratoconjunctivitis
HPO:Keratoconjunctivitis

Primary Outcomes

Description: eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling

Measure: Symptom improvement

Time: 10-15 days

Description: conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva

Measure: Signs improvement

Time: 10-15 days


HPO Nodes